Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

The maker of EpiPen sticks it to patients

Monique Tello, MD
Meds
August 31, 2016
575 Shares
Share
Tweet
Share

Recently, friends of ours had a frightening experience: They were on vacation, and ordered takeout from an unfamiliar restaurant. They specifically asked about peanuts: “Are the egg rolls fried in peanut oil? Our daughter has an allergy.”

The server replied: “No, no peanut oil.”

And so they ordered the egg rolls.

Awhile after eating an egg roll, their school-aged child Anna (not her real name) complained of a tummy ache. Then, nausea. They thought maybe she’d eaten too quickly, or too much.

Suddenly, she started sneezing, sneezing repeatedly and uncontrollably, and wheezing. “Pollen,” they thought. “She’s been running around outside with the other kids.” They gave her a Benadryl.

But within a minute or two, she broke out into hives, and her face started to swell.

“Oh my God,” realized her mom. “This is anaphylactic shock.”

Anaphylactic shock is a severe allergic reaction that can result in such massive swelling that a person’s airway is choked off, and their blood pressure can drop to shock levels. Horrified, she yelled to her partner: “We need to go to the emergency room, Now!”

She fetched the EpiPen, but was too upset to administer it, so she threw it to her partner, who ripped off the top and injected the medication into Anna’s thigh. Then, they ran to the car.

They were barely out of the driveway when Anna observed, “I’m breathing a little better, now.”

The EpiPen effects wear off quickly, and it’s common for patients to require a second injection (that’s why there are two to a pack). But the ER nurses were able to get an IV and give steroids and antihistamines, and after six hours,  Anna was able to go home.

Later on, they learned that no, the egg rolls were not fried in peanut oil. But, they actually have peanut butter in them. It was almost a deadly miscommunication.

The whole episode was awful, but it could have been so much worse: The two other children on the trip are also seriously allergic to peanuts. They just hadn’t eaten any egg rolls, for some reason. If they had, the two EpiPens they had with them would not have been enough. There may have been a very different ending to the story.

Our friends need to have multiple EpiPens for each child: A set of two for every place the children are cared for, including school, their after-school program, and home. They have excellent insurance, but regardless, the co-pays for all the very medically necessary EpiPens now end up totaling several hundred dollars.

EpiPens didn’t always cost this much.

Business and investment website The Motley Fool has published a very nice concise history of the EpiPen price inflation. Basically, epinephrine as a medication was developed in Germany in 1904, and has been available via vial and syringe for as long. However, in an emergency like Anna’s, a vial-and-syringe delivery system can be problematic, resulting in delays and dosing errors. It’s hard to think straight when your kid is blowing up in front of you.

The EpiPen is an automatic delivery system of the correct dose via a spring-loaded needle, and has been available since the 1980’s. The convenient drug-and-delivery system originally cost less than $100, but then Mylan Pharmaceuticals acquired the company. The only reasonable competitor device, Sanofi pharmaceutical’s Auvi-Q, was pulled amidst concerns for malfunction. Since then, Mylan’s EpiPen has owned the market, and they know it. A series of relentless price hikes has ensued, and now a pair of pens costs over $600.

Sales of EpiPen nets Mylan approximately a billion dollars annually, and Mylan’s shameless CEO Heather Bresch has hiked her salary accordingly, to a ridiculous twenty million dollars. 

Bresch and Mylan have been appropriately pounded with criticism, and have reacted by tossing out a few band-aid public-relations driven provisions: A coupon is available for the uninsured, but they have to jump through a whole bunch of hoops to get it.

Meantime, even families with good insurance are burdened by heavy, heavy co-pays, but they have no choice, unless they feel they can accurately draw up the correct dose via needle and syringe while under duress, and trust all of their child’s teachers and caretakers to do so as well. Epinephrine, which is a synthetic form of the hormone adrenaline, causes the heart rate and blood pressure to increase. Either an under- or over-dosing can have serious clinical consequences.

This is obviously corporate greed at its worst. But what can we do?

A pediatric neurologist friend of mine has made a clever suggestion: Hit them where it hurts the most, meaning, their wallet.

Mylan is a massive company that makes a large number of generic drugs, from antibiotics like doxycycline, to antipsychotics like risperidone, to cancer treatments like Tamoxifen. Her idea specifically: “What if all the prescribing docs agreed to write prescriptions with the annotation, ‘Please dispense any alternative to Mylan products if possible,’ so that the pharmacist could then dispense another company’s generic?”

This may be feasible. For me, that would mean a cut-and-paste text sentence at the bottom of the electronic prescription, an addendum that only the pharmacist sees. It’s simple. If enough physicians get in on the game, we could make a sizable dent in Mylan’s profits.

I’m wondering what my physician colleagues think about this.

Meantime, Mylan’s official website boasts their company motto: “Why Mylan? Because our passion, innovation, and commitment drive us to set new standards in health care. Seeing is believing.”

They’ve set a new standard, all right: A disappointing, frustrating, abysmally low industry standard.

Update: Mylan announced it will sell a generic version of its own product for $300. As many have pointed out, it’s still expensive, but, it’s better than $600. I still cringe at the thought of supporting this company.

Monique Tello is an internal medicine physician who blogs at generallymedicine.  

Image credit: Amy Kerkemeyer / Shutterstock.com

Prev

Why psychiatrists should stop diagnosing presidential candidates

August 31, 2016 Kevin 5
…
Next

Mylan Pharmaceuticals made these 2 critical mistakes

August 31, 2016 Kevin 24
…

Tagged as: Pediatrics

Post navigation

< Previous Post
Why psychiatrists should stop diagnosing presidential candidates
Next Post >
Mylan Pharmaceuticals made these 2 critical mistakes

More by Monique Tello, MD

  • Leaving academic medicine was a matter of self-respect

    Monique Tello, MD
  • Leaving clinical medicine without regrets

    Monique Tello, MD
  • When physicians are cyberbullied: an interview with ZDoggMD

    Monique Tello, MD

Related Posts

  • Are patients using social media to attack physicians?

    David R. Stukus, MD
  • You are abandoning your patients if you are not active on social media

    Pat Rich
  • How to help your patients understand antibiotic stewardship

    Greg Gafni-Pappas, DO
  • When Western medicine fails patients and clinicians

    Kimberly Rogers, MD
  • Cancer patients who want to take unproven supplements

    Marc Braunstein, MD, PhD
  • Your patients are counting on you

    Adam Striker, MD

More in Meds

  • The real cause of America’s opioid crisis: Doctors are not to blame

    Richard A. Lawhern, PhD
  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • Why North American medical cannabis can’t compete globally

    Michael Sassano
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Caught in the middle: How health insurance companies influence cancer drug selection

    Paul Pender, MD
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • The struggle to fill emergency medicine residency spots: Exploring the factors behind the unfilled match

      Katrina Gipson, MD, MPH | Physician
    • Breaking the stigma: Addressing the struggles of physicians

      Jean Antonucci, MD | Physician
    • Beyond the disease: the power of empathy in health care

      Nana Dadzie Ghansah, MD | Physician
    • Deaths of despair: an urgent call for a collective response to the crisis in U.S. life expectancy

      Mohammed Umer Waris, MD | Policy
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Do residents deserve the title of physician?

      Anonymous | Physician
    • A new era of collaboration between AI and health care professionals

      Harvey Castro, MD, MBA | Tech
    • When an MBA degree meets medicine: an eye-opening experience

      Arthur Lazarus, MD, MBA | Physician
    • Why it’s time to question medical traditions [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden gems of health care: Unlocking the potential of narrative medicine

      Dr. Najat Fadlallah | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 27 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Health Inequity Should Be Labeled as a 'Never Event'
  • Healing the Damaged Nurse-Physician Dynamic
  • Doc Moms, Mind the Gap -- $3M Earning Difference by Sex
  • Clinical Note Writing App Powered by GPT-4 Set to Debut This Year
  • Helping Patients Get Fit -- One Walk at a Time

Meeting Coverage

  • Switch to IL-23 Blocker Yields Deep Responses in Recalcitrant Plaque Psoriasis
  • Biomarkers of Response With Enfortumab Vedotin in Advanced Urothelial Cancer
  • At-Home Topical Therapy for Molluscum Contagiosum Gets High Marks
  • Outlook for Itchy Prurigo Nodularis Continues to Improve With IL-31 Antagonist
  • AAAAI President Shares Highlights From the 2023 Meeting
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • The struggle to fill emergency medicine residency spots: Exploring the factors behind the unfilled match

      Katrina Gipson, MD, MPH | Physician
    • Breaking the stigma: Addressing the struggles of physicians

      Jean Antonucci, MD | Physician
    • Beyond the disease: the power of empathy in health care

      Nana Dadzie Ghansah, MD | Physician
    • Deaths of despair: an urgent call for a collective response to the crisis in U.S. life expectancy

      Mohammed Umer Waris, MD | Policy
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Do residents deserve the title of physician?

      Anonymous | Physician
    • A new era of collaboration between AI and health care professionals

      Harvey Castro, MD, MBA | Tech
    • When an MBA degree meets medicine: an eye-opening experience

      Arthur Lazarus, MD, MBA | Physician
    • Why it’s time to question medical traditions [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden gems of health care: Unlocking the potential of narrative medicine

      Dr. Najat Fadlallah | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

The maker of EpiPen sticks it to patients
27 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...